Mercado mundial del melanoma: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado del melanoma

Se espera que el mercado mundial del melanoma experimente un crecimiento significativo durante el período de pronóstico. En los últimos años, se ha observado un aumento en el número de nuevos casos debido a los cambios climáticos. Estos cambios están aumentando la incidencia de pacientes con melanoma en todo el mundo, lo que aumenta la demanda de métodos de tratamiento adecuados. Entre los diversos tratamientos, el segmento de quimioterapia tuvo una participación de mercado sustancial en 2020. COVID-19 también tuvo un impacto importante en el crecimiento del mercado.

Data Bridge Market Research analiza la tasa de crecimiento del mercado del melanoma en el período de pronóstico 2022-2029. La CAGR esperada del mercado del melanoma tiende a rondar el 11,8% en el período de pronóstico mencionado. El mercado se valoró en 5.370 millones de dólares en 2021 y crecería hasta 13.110 millones de dólares en 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado seleccionado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología de los pacientes, análisis de la cartera de proyectos, análisis de precios y marco regulatorio.

Definición de mercado

El melanoma es un tipo de cáncer de piel en el que las células cancerosas se desarrollan en las células productoras de pigmento llamadas melanocitos. También puede afectar a los ojos y, muy raramente, a la nariz o la garganta. Los pacientes que padecen melanoma generalmente desarrollan un crecimiento inusual en un lunar existente. El melanoma se considera el más mortal de estos tres tipos de cáncer de piel. Los genes y las radiaciones ultravioleta son los principales responsables de causar melanoma. Además del cáncer, también están aumentando diversas alergias e infecciones cutáneas, lo que funciona bien para la industria de los tratamientos y la terapéutica de la piel. 

Alcance y segmentación del mercado del melanoma

Global Melanoma Market Dynamics

Drivers

• Notable Developments in terms of Market Players

Recently, there have been some promising and innovative developments in the global melanoma market. The market has observed the presence of several noticeable market players with each of the players competing for more revenue and greater reach. Relentless research and development activities has played a critical role in the expansion of the share of the market and growing revenue for the market players. This boosts the market growth.

• Increasing Demand of Targeted Therapy

The rising demand for targeted therapy showed many advantages as it interferes with specific proteins involved in tumorigenesis focusing on specific molecular changes, which stop the growth of various types of cancers. Several significant factors influenced melanoma growth, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts the market growth.

• Increase in Skin Cancer

As per the records of WHO, around 132,000 cases of skin cancer occur each year. Furthermore, a 10% reduction in ozone levels is predicted to lead to an increase of 4,500 skin cancer cases worldwide. This is projected to increase the demand for these drugs during the forecast period.

Opportunities

• Growing Healthcare Infrastructure and Policies

The presence of large patient pool, having a strong presence of key players, ease of drug availability, a well-established healthcare infrastructure, favourable reimbursement policies in the healthcare system, rise in R&D, and innovation activities and higher adoption of advanced therapeutics may create opportunities for the market.    

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs for mesothelioma delivered via retail pharmacies and the rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

• Growing Regulatory Approvals

The high emphasis and, subsequently the elevated investment in developing efficient treatment options are most likely to have an encouraging impact on the market's growth. Treatment recommendations depend on many factors, and the growing number of regulatory approvals has significantly impacted market growth. For instance, in 2021, Aldesleukin, Binimetinib, Braftovi, Cobimetinib Fumarate, Cotellic, Dabrafenib Mesylate were some of the approved drugs used for the treatment by FDA. The importance of major companies on introducing innovative treatment options and drugs will support the market growth in the coming years.

 Restraints/Challenges

• Unavailability of Appropriate Treatments

To treat conditions that are rare, many a times all treatments are not available, especially in under-developed countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.

• High Cost

The huge expenditure associated with the several treatment methods such as chemotherapy, and targeted therapy which are in high demand in recent years hamper the market growth.

This global melanoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global melanoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Melanoma Market

The pandemic has significantly affected numerous diagnostic methods because of several restrictions and risk exposure of comorbidity patients. A drastic decrease in skin biopsies was seen early in the COVID-19 pandemic, which unreasonably affected the elderly, females, and certain geographic regions. However, efforts have been made by the government to contain the situation in the post-pandemic era.

Recent Development:

In 2020, FDA approved the drug selumetinib of AstraZeneca and Merck & Co. to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease that causes tumors to grow inside nerve sheaths. In addition to this, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Global Melanoma Market Scope

The global melanoma market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Melanoma Market Regional Analysis/Insights

The global melanoma market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global melanoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global melanoma market throughout the forecasted period due to the increase awareness about the diseases and rapidly disposable income.

North America dominates the market due  to the increase prevalence of melanoma, strong research and development activity by key players, high demand of targeted therapies and advanced healthcare facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Melanoma Market Share Analysis

The global melanoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global melanoma market.

Key players operating in the global melanoma market include:

• Johnson & Johnson Private Limited (U.S.)
• Mylan N.V. (U.S.)
• Industrias farmacéuticas Sun Limited (India)
• Sanofi SA (Francia)
• Bayer AG (Alemania)
• Lilly (Estados Unidos)
• Merck & Co., Inc. (Estados Unidos)
• GSK plc (Reino Unido)
• Novartis AG (Suiza)
• AbbVie Inc. (Estados Unidos)
• Exelixis, Inc. (Estados Unidos)
• Aptose Biosciences Inc. (Canadá)

SKU-54303